FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> breast cancer | ovarian cancer vaccine | PANVAC

PANVAC for breast, ovarian cancer shows early promise

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

A study of 26 women with breast and ovarian cancer found that the PANVAC vaccine helped the immune system recognize and destroy tumor cells. The trial was conducted at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, with results published in the journal Clinical Cancer Research.

Of the 26 women tested, all had exhausted other treatment options and had cancer that spread to other parts of the body. Of the 12 patients with breast cancer, PANVAC delayed disease progression 2.5 months, with a median overall survival of 13.7 months. Four patients had stable disease, and one woman's cancer disappeared. Of the 14 patients in the ovarian cancer group, the vaccine delayed progression two months with a median overall survival of 15 months.

"With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients," said lead researcher Dr. James Gulley in a release. "The sustained benefit seen in some patients in this study underscores the potential for therapeutic vaccines to impact clinical outcomes without toxicity. However, more studies in the appropriate patient populations are required to adequately assess efficacy."

- take a look at the release
- here's the HealthDay report for more

Special Report: 10 Promising Therapeutic Vaccines


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about breast cancer   ovarian cancer vaccine   PANVAC